Sagimet Biosciences Inc
NASDAQ:SGMT

Watchlist Manager
Sagimet Biosciences Inc Logo
Sagimet Biosciences Inc
NASDAQ:SGMT
Watchlist
Price: 6.28 USD 1.45% Market Closed
Market Cap: 202.2m USD

Sagimet Biosciences Inc
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Sagimet Biosciences Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Sagimet Biosciences Inc
NASDAQ:SGMT
Cash & Cash Equivalents
$75.8m
CAGR 3-Years
10%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash & Cash Equivalents
$5.6B
CAGR 3-Years
-22%
CAGR 5-Years
-7%
CAGR 10-Years
-5%
Gilead Sciences Inc
NASDAQ:GILD
Cash & Cash Equivalents
$9.4B
CAGR 3-Years
26%
CAGR 5-Years
-6%
CAGR 10-Years
-4%
Amgen Inc
NASDAQ:AMGN
Cash & Cash Equivalents
$9.4B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash & Cash Equivalents
$6.3B
CAGR 3-Years
-12%
CAGR 5-Years
3%
CAGR 10-Years
24%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash & Cash Equivalents
$2.5B
CAGR 3-Years
-10%
CAGR 5-Years
10%
CAGR 10-Years
14%
No Stocks Found

Sagimet Biosciences Inc
Glance View

Market Cap
204.2m USD
Industry
Biotechnology

Sagimet Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Mateo, California and currently employs 10 full-time employees. The company went IPO on 2023-07-14. Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). In addition to NASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase II clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.

SGMT Intrinsic Value
Not Available

See Also

What is Sagimet Biosciences Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
75.8m USD

Based on the financial report for Dec 31, 2024, Sagimet Biosciences Inc's Cash & Cash Equivalents amounts to 75.8m USD.

What is Sagimet Biosciences Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
49%

Over the last year, the Cash & Cash Equivalents growth was 1%. The average annual Cash & Cash Equivalents growth rates for Sagimet Biosciences Inc have been 10% over the past three years , 49% over the past five years .

Back to Top